skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Oxford Journals remover Base de dados/Biblioteca: ScienceDirect Additional Titles remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

Qin, S. ; Chan, L.S. ; Gu, S. ; Bai, Y. ; Ren, Z. ; Lin, X. ; Chen, Z. ; Jia, W. ; Jin, Y. ; Guo, Y. ; Sultanbaev, A.V. ; Pazgan-Simon, M. ; Pisetska, M. ; Liang, X. ; Chen, C. ; Nie, Z. ; Wang, L. ; Cheng, A-L. ; Kaseb, A. ; Vogel, A.

Annals of oncology, 2022-09, Vol.33, p.S1401-S1402 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
2
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)

Schmid, P. ; Cortés, J. ; Dent, R. ; Pusztai, L. ; McArthur, H.L. ; Kuemmel, S. ; Bergh, J. ; Denkert, C. ; Park, Y.H. ; Hui, R. ; Harbeck, N. ; Takahashi, M. ; Foukakis, T. ; Fasching, P.A. ; Cardoso, F. ; Jia, L. ; Karantza, V. ; Zhao, J. ; Aktan, G. ; O’Shaughnessy, J.

Annals of oncology, 2019-10, Vol.30, p.v853-v854 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
3
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)

Cascone, T. ; William, W.N. ; Weissferdt, A. ; Leung, C.H. ; Federico, L. ; Haymaker, C. ; Bernatchez, C. ; Fossella, F.V. ; Mott, F.E. ; Papadimitrakopoulou, V.A. ; Byers, L. ; Lam, V.K. ; Godoy, M.C. ; Carter, B. ; Lee, J.J. ; Vaporciyan, A. ; Gibbons, D.L. ; Swisher, S.G. ; Heymach, J.V. ; Sepesi, B.

Annals of oncology, 2018-10, Vol.29, p.viii738-viii738 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
Material Type:
Artigo 		Adicionar ao Meu Espaço

NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC

Socinski, M. ; Creelan, B. ; Horn, L. ; Reck, M. ; Paz-Ares, L. ; Steins, M. ; Felip, E. ; van den Heuvel, M. ; Ciuleanu, T.E. ; Badin, F. ; Ready, N. ; Hiltermann, T.J.N. ; Nair, S. ; Juergens, R. ; Peters, S. ; Minenza, E. ; Geese, W.J. ; Bhagavatheeswaran, P. ; Chen, A. ; Carbone, D.P.

Annals of oncology, 2016-10, Vol.27, p.vi577-vi577 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
5
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

Ramalingam, S.S. ; Cheng, Y. ; Zhou, C. ; Ohe, Y. ; Imamura, F. ; Cho, B.C. ; Lin, M.-C. ; Majem, M. ; Shah, R. ; Rukazenkov, Y. ; Todd, A. ; Markovets, A. ; Barrett, J.C. ; Chmielecki, J. ; Gray, J.

Annals of oncology, 2018-10, Vol.29, p.viii740-viii740 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Material Type:
Artigo 		Adicionar ao Meu Espaço

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

Herbst, R.S. ; Baas, P. ; Kim, D.-W. ; Felip, E. ; Pérez-Gracia, J.L. ; Han, J.-Y. ; Molina, J. ; Kim, J.-H. ; Arvis, C. Dubos ; Ahn, M.-J.A. ; Majem, M. ; Fidler, M.J. ; De Castro, G. ; Garrido, M. ; Shentu, Y. ; Lubiniecki, G.M. ; Garon, E.B.

Annals of oncology, 2016-10, Vol.27, p.vi583-vi583 [Periódico revisado por pares]

Elsevier Ltd

Texto completo disponível

Citações Citado por
7
ESMO-Magnitude of Clinical Benefit Scale version 1.1
ESMO-Magnitude of Clinical Benefit Scale version 1.1
Material Type:
Artigo 		Adicionar ao Meu Espaço

ESMO-Magnitude of Clinical Benefit Scale version 1.1

Cherny, N.I. ; Dafni, U. ; Bogaerts, J. ; Latino, N.J. ; Pentheroudakis, G. ; Douillard, J.-Y. ; Tabernero, J. ; Zielinski, C. ; Piccart, M.J. ; de Vries, E.G.E.

Annals of oncology, 2017-10, Vol.28 (10), p.2340-2366 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)

Pishvaian, M.J. ; Lee, M.S. ; Ryoo, B.-Y. ; Stein, S. ; Lee, K.-H. ; Verret, W. ; Spahn, J. ; Shao, H. ; Liu, B. ; Iizuka, K. ; Hsu, C.-H.

Annals of oncology, 2018-10, Vol.29, p.viii718-viii719 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

André, F. ; Ciruelos, E.M. ; Rubovszky, G. ; Campone, M. ; Loibl, S. ; Rugo, H.S. ; Iwata, H. ; Conte, P. ; Mayer, I.A. ; Kaufman, B. ; Yamashita, T. ; Lu, Y.-S. ; Inoue, K. ; Takahashi, M. ; Pápai, Z. ; Longin, A.-S. ; Mills, D. ; Wilke, C. ; Hirawat, S. ; Juric, D.

Annals of oncology, 2018-10, Vol.29, p.viii709-viii709 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
10
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Material Type:
Artigo 		Adicionar ao Meu Espaço

LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

Finn, R.S. ; Kudo, M. ; Merle, P. ; Meyer, T. ; Qin, S. ; Ikeda, M. ; Xu, R. ; Edeline, J. ; Ryoo, B-Y. ; Ren, Z. ; Cheng, A-L. ; Galle, P.R. ; Kaneko, S. ; Kumada, H. ; Wang, A. ; Mody, K. ; Dubrovsky, L. ; Siegel, A.B. ; Llovet, J.

Annals of oncology, 2022-09, Vol.33, p.S1401 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (12.507)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (12.482)
  2. Anais de Congresso  (18)
  3. Web Resources  (13)
  4. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1996  (1.202)
  2. 1996Até2002  (2.452)
  3. 2003Até2009  (3.101)
  4. 2010Até2017  (4.131)
  5. Após 2017  (1.628)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (12.511)
  2. Japonês  (2.024)
  3. Russo  (40)
  4. Norueguês  (7)
  5. Alemão  (2)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.